TRIGR Therapeutics, ABL Bio sign license agreement for bispecific antibody candidate

This article was originally published here

The license agreement is exclusive and global, excluding the Republic of Korea for all oncology indications and excluding the Republic of Korea and Japan for all ophthalmology indications.

The post TRIGR Therapeutics, ABL Bio sign license agreement for bispecific antibody candidate appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply